• Profile

Development and evaluation of serum CST1 detection for early diagnosis of esophageal squamous cell carcinoma

Cancer Management and Research Nov 10, 2021

Wang J, Yu L, Sun Y, et al. - Findings demonstrate excellent detection performance of a chemiluminescent enzyme immunoassay (CLEIA) for cystatin SN (CST1) protein, which might serve as a prospective serological biomarker for early diagnosis of esophageal squamous cell carcinoma (ESCC).

  • In a pilot study, a high expression of CST1 protein in ESCC tissues has been shown.

  • This study involved 112 early ESCC, 107 esophageal benign lesions, and 151 healthy controls.

  • CLEIA developed in this study showed linear range and detection limit of 6.25– 400 pg/mL and 1.35 pg/mL, respectively, for CST1; average recovery rate was 102.65%; coefficients of variation of intra-batch precision and inter-batch precision were < 1/4 total error allowance (TEa) and < 1/3 TEa, respectively; and good sample and reagent stability.

  • CST1 had a diagnostic sensitivity of 31.25% for early ESCC (specificity 92.64%, AUC 0.654).

  • Conventional tumor markers showed diagnostic sensitivity ranging from 16.07% to 28.57%, at > 93.0% specificity, and SCC-Ag demonstrated the highest AUC (0.709).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen